A further study by Martinotti et al.33focused on biological correlates by conducting an 8‐week open‐label study of 27 patients with depressive disorders spectrum to assess the impact of agomelatine (25–50 mg/day) on serum BDNF levels and their correlation with clinical improvements. Here, BDNF is linked to depressive disorder.